Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-07-31
2007-07-31
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S228100
Reexamination Certificate
active
10466242
ABSTRACT:
The present invention relates to materials and methods for treatment of hepatitis C. More closely, the invention relates to human monoclonal antibodies against HCV E1 antigen, to a reagent comprising such antibodies, and to vaccine compositions comprising such antibodies. Futhermore, the invention relates to a method of treating or preventing HCV infection by administration of a vaccine composition comprising the monoclonal antibodies of the invention.
REFERENCES:
patent: 6150134 (2000-11-01), Maertens et al.
patent: 6538114 (2003-03-01), Persson et al.
patent: 6692908 (2004-02-01), Foung et al.
patent: 6747136 (2004-06-01), Persson et al.
patent: 2003/0180284 (2003-09-01), Foung et al.
patent: WO 97/40176 (1997-10-01), None
patent: WO00/26418 (2000-05-01), None
patent: WO02/057314 (2002-07-01), None
patent: WO2004/005316 (2004-01-01), None
Saadeh et al. Cleveland Clinic Journal of Medicine, 2004, vol. 71, supplement 3, pp. S3-S7.
McHutchinson et al. Hepatology, 2002, 36 :S245-252.
Berzofsky et al. The Journal of Clinical Investigation, 2004, 114(4):450-462.
Colman, P.M. Effects of amino acid sequence changes on antibody-antigen interactions, Research Immunology, Jan. 1994, vol. 145, pp. 33-36.
Bartosch, B. et al. “Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1-E2 Envelope Protein Complexes”; The Journal of Experimental Medicine, 197(5): 633-642 (2003).
Hsu, M. et al. “Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles”; PNAS, 100(12): 7271-7276 (2003).
De Beeck, A.O. et al. “Characterization of Functional Hepatitis C. Virus Envelope Glycoproteins”; Journal of Virology, 78(6): 2994-3002 (2004).
Logvinoff, C. et al. “Neutralizing antibody response during acute and chronic hepatitis C virus infection”; PNAS, 101(27): 10149-10154 (2004).
Keck, Z. et al. “Human Monoclonal Antibody to Hepatitis C Virus E1 Glycoprotein That Blocks Virus Attachment and Viral Infectivity”; Journal of Virology, 78(13): 7257-7263 (2004).
Burioni, R. et al. “Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection”; Virology, 327: 242-248 (2004).
Ludwig, I.S. et al. “Hepatitis C Virus Targets DC-SIGN and L-SIGN To Escape Lysosomal Degradation”; Journal of Virology, 78(15): 8322-8332 (2004).
McKeating, J.A. et al. “Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner”; Journal of Virology, 78(16): 8496-8505 (2004).
Taguchi, H. et al. “Antibody light chain-catalyzed hydrolysis of a hepatitis C virus peptide”; Bioorganic & Medicinal Chemistry Letters, 14: 4529-4532 (2004).
Drakenberg Katarina
Persson Mats A. A.
Chen Stacy B.
Dann Dorfman Herrell & Skillman
Molecules of Man AB
Rigaut Kathleen D.
LandOfFree
Human monoclonal antibodies that bind hepatitis C virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies that bind hepatitis C virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies that bind hepatitis C virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3724237